Outlook Therapeutics, Inc.
OTLK$27M
Micro CapNASDAQBiological Products, (No Diagnostic Substances)🇺🇸North AmericaISELIN23 employees
Drugs in Pipeline
2
Phase 3 Programs
2
Upcoming Catalysts
2
Next Catalyst
Mar 1, 2026
21dData is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply
Market Overview
Stock performance and market intelligence
Catalyst Timeline
2 upcoming, 0 past
🎯PDUFANext
FDA PDUFA Date ONS-5010 / LYTENAVA (standard)
3/1/2026
For wet age-related macular degeneration. BLA filing. Extracted from SEC filing: 8-K
Source🎯PDUFA
FDA PDUFA Date ONS-5010 (standard)
3/23/2026
For wet age-related macular degeneration (wet AMD). BLA filing. Extracted from SEC filing: 8-K
SourceAI Predictions & Institutional Flow
Machine learning insights and smart money movement
FDA Submissions
Pending NDA/BLA submissions with predicted PDUFA dates
Drug Pipeline
Clinical development programs and drug candidates
Drug Pipeline
bevacizumab
Age-related Macular Degeneration
ranibizumab
Age-related Macular Degeneration
| Drug Name | Phase | Indication | Designations |
|---|---|---|---|
bevacizumab | Phase 3 | Age-related Macular Degeneration | - |
ranibizumab | Phase 3 | Age-related Macular Degeneration | - |
Regulatory & News
Approvals, filings, and latest developments
Regulatory Approvals
OTLK News